An Alternative Alcobra (ADHD) Trade
Research - Alcobra Pharma (ADHD) announced on September 19 that all scheduled follow-up visits had been complete in the company’s phase 3 clinical trial of metadoxine in … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
J&J Puts Up $2 Billion for Viral Therapeutics, Spotlights Two Other Public Companies
Insights - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset is compound … Continue Reading
Read now
Firdapse, Catalyst Pharma Produce Phase 3 Success
Insights - Catalyst Pharmaceuticals’ (CPRX) Firdapse (amifampridine phosphate) hit both co-primary endpoints successfully in a phase 3 trial in Lamberton-Eaton myasthenic syndroms (LEMS), announced on Monday afternoon. The stock climbed 20% … Continue Reading
Read now
The Liver is Hot in Biotech. All Eyes on November
Recap - November is approaching, and the AASLD’s Liver Meeting conference the second week of the month, attracting a bevy of investors this year. The liver has become … Continue Reading
Read now
Latest Must-Knows for Arrowhead Research
Insights - Arrowhead Research (ARWR) presented on Friday at Biocentury’s Newsmakers in the Biotech Industry conference. Investors are paying close attention given an important data event in November for ARC-520 … Continue Reading
Read now
Cempra’s Phase 3 Trial Enrolled Faster than Expected
Insights - Cempra, Inc. (CEMP) enrolled patients in SOLITAIRE-Oral, a phase 3 trial of lead antibiotic solithromycin, slightly faster than expected, announcing completion on Thursday that puts a … Continue Reading
Read now
Over-Optimism Comes Back to Bite AcelRx Following FDA Meeting
Insights - Following a teleconference with the FDA, AcelRx Pharmaceuticals (ACRX) says that a resubmission of the Zalviso New Drug Application won’t occur until the first quarter … Continue Reading
Read now